Riyadh Valley Company (RVC) announces its investment in Global Kinetics Pty Ltd (GK). GK is an Australian novel digital health company that is revolutionizing the management of Parkinson’s disease by providing the first continuous and objective measurement of patients’ symptoms in everyday environments.
The company’s Personal KinetiGraph® (PKG®) is a patient-friendly, algorithm-based system that records patients’ movements over the course of several days and creates data-driven reports that empowers more personalized treatment and management decisions—ultimately leading to a higher quality of life for patients.
The PKG® system is being used in clinics across the U.S., Europe and Asia Pacific, enabling better clinical outcomes and reducing health care costs across the Parkinson’s disease continuum. Global Kinetics continues to pursue partnerships with major pharmaceutical and medical technology companies to help measure efficacy of new and advanced therapies for one of the world’s most widespread movement disorders.
Dr. Khalid Al-Saleh, the CEO of Riyadh Valley Company said: “Investment in Health & life sciences is one of our goals; especially in companies that have experience in health-tech, and have number of patents globally such as, USA, Europe, and Australia. Our aim in RVC is to grow our portfolio investments locally and internationally”.
Riyadh Valley Company joined leading international investors in this financing, including Brandon Capital, manager of the Medical Research Commercialization Fund, BioScience Managers and Korea Investment Partners. Global Kinetics was established in 2007 to commercialize innovative technology developed by Professor Malcolm Horne, from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr. Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease and lead by J Leighton Read, MD who has a long career starting and funding successful biomedical companies in Silicon Valley following his internal medicine training at Duke and Harvard Medical School.
This investment comes within Riyadh Valley Company investment sectors and contributes to build a balanced local and international portfolio according to an investment strategy that achieves King Saud University’s goals and contributes to the economic development of the Kingdom of Saudi Arabia to achieve the Kingdom’s 2030 vision.